Glioblastoma Clinical Trials in Dallas, TX

View the best 10 glioblastoma medical studies in Dallas, Texas. Access promising new therapies by applying to a Dallas-based Glioblastoma clinical trial.

Trials in Dallas, Texas

Here are the top 8 medical studies for glioblastoma in Dallas, Texas

Carboplatin

Chemotherapy

Recruiting2 awardsPhase 3

This trial tests a new method to treat recurrent brain cancer using an ultrasound device called SonoCloud-9. The device helps open the brain's protective barrier so that more of the chemotherapy drug carboplatin can reach the tumor. The goal is to see if this combination makes the treatment more effective. Carboplatin has been used in various studies for treating high-grade gliomas and glioblastomas, often showing modest efficacy due to low tissue concentration when delivered intravenously.

GammaTile radiation therapy implantation +3 More

Brachytherapy

Recruiting3 awardsPhase 4

This trial tests if adding GammaTile radiation therapy to standard treatment can improve outcomes for patients with newly diagnosed GBM. GammaTile delivers quick, direct radiation to the tumor, which may help control the tumor better and improve survival rates.

Optune®

Device

Recruiting1 award12 criteria

This trial is testing a new treatment for brain cancer that combines Optune with radiation and chemotherapy. The goal is to see if this new combination is more effective and has fewer side effects than current treatments.

Sacituzumab Govitecan

Monoclonal Antibodies

Recruiting1 awardPhase 2

This trial is testing a new treatment or drug on all patients in the study to see if it is effective and safe.

Temozolomide +2 More

Alkylating agents

Recruiting1 awardPhase 2

This trial is studying how well two types of radiation therapy work compared to standard radiation therapy when given with temozolomide in patients with newly diagnosed glioblastoma.

Lomustine +2 More

Alkylating agents

Recruiting2 awardsPhase 3

This trial is comparing the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in treating newly diagnosed MGMT methylated glioblastoma.

Temozolomide

Alkylating agents

Recruiting0 awardsPhase 2 & 3

This trial is studying the combination of temozolomide and veliparib compared to temozolomide alone in treating patients with newly diagnosed glioblastoma multiforme.

Radiation Therapy +2 More

Radiation

Recruiting1 awardPhase 2

This trial is studying a combination of drugs as a potential treatment for newly diagnosed malignant glioma. The drugs being studied are veliparib, radiation therapy, and temozolomide.

Popular Filters

Trials With No Placebo

Chemotherapy

Ultrasound-Assisted Chemotherapy for Glioblastoma

Recruiting2 awardsPhase 3

Dallas, Texas

This trial tests a new method to treat recurrent brain cancer using an ultrasound device called SonoCloud-9. The device helps open the brain's protective barrier so that more of the chemotherapy drug carboplatin can reach the tumor. The goal is to see if this combination makes the treatment more effective. Carboplatin has been used in various studies for treating high-grade gliomas and glioblastomas, often showing modest efficacy due to low tissue concentration when delivered intravenously.

Brachytherapy

GammaTile + Stupp Protocol for Glioblastoma

Recruiting3 awardsPhase 4

Dallas, Texas

This trial tests if adding GammaTile radiation therapy to standard treatment can improve outcomes for patients with newly diagnosed GBM. GammaTile delivers quick, direct radiation to the tumor, which may help control the tumor better and improve survival rates.

Small Molecule Inhibitor

BDTX-1535 + Temozolomide for Glioblastoma and Lung Cancer

Recruiting1 awardPhase 1 & 2

Dallas, Texas

This trial is testing a new drug for people with glioblastoma or non-small cell lung cancer who have disease progression following standard of care.

Alkylating agents

Lomustine + Standard Therapy for Glioblastoma

Recruiting2 awardsPhase 3

Oklahoma City, Oklahoma

This trial is comparing the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in treating newly diagnosed MGMT methylated glioblastoma.

Monoclonal Antibodies

NGM707 + Pembrolizumab for Cancer

Recruiting1 awardPhase 1 & 2

Dallas, Texas

This trial is testing a new drug called NGM707, both by itself and with another drug, Pembrolizumab. It targets patients with very advanced or spreading solid tumors. The treatment aims to boost the immune system to better fight cancer.

Chemotherapy

NMS-03305293 + Temozolomide for Glioblastoma

Recruiting1 awardPhase 1 & 2

Dallas, Texas

This trial is testing a new combination of drugs to treat adults with gliomas, with the goal of finding a safe and effective treatment.

View More Related Trials

Frequently Asked Questions

Do I need insurance to participate in a trial?

Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).

Is there any support for travel costs?

Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.

Will I know what medication I am taking?

This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.

How long do clinical trials last?

Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.

Do you verify all the trials on your website?

All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.

How quickly will I hear back from a clinical trial?

Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.